# Comprehensive Research Plan: 1000 Experiments

**Project**: HIV Drug Resistance Prediction
**Current Baseline**: +0.88 average Spearman correlation
**Goal**: Systematic exploration of every possible improvement

---

## Category 1: Model Architecture (1-100)

### Encoder Variants (1-25)
1. Test 1-layer encoder (minimal)
2. Test 2-layer encoder
3. Test 3-layer encoder (current)
4. Test 4-layer encoder
5. Test 5-layer encoder (deep)
6. Test 6-layer encoder
7. Test hidden dims [64, 32]
8. Test hidden dims [128, 64]
9. Test hidden dims [256, 128, 64]
10. Test hidden dims [512, 256, 128]
11. Test hidden dims [1024, 512, 256]
12. Test pyramidal dims [256, 128, 64, 32]
13. Test reverse pyramid [32, 64, 128, 256]
14. Test bottleneck [256, 32, 256]
15. Test wide-shallow [512, 512]
16. Test narrow-deep [64, 64, 64, 64, 64]
17. Test skip connections in encoder
18. Test dense connections (DenseNet-style)
19. Test highway networks
20. Test residual blocks in encoder
21. Test squeeze-excitation blocks
22. Test inverted residuals (MobileNet-style)
23. Test depthwise separable convolutions
24. Test 1D convolutions before MLP
25. Test dilated 1D convolutions

### Decoder Variants (26-50)
26. Test symmetric decoder
27. Test asymmetric decoder (smaller)
28. Test asymmetric decoder (larger)
29. Test decoder with skip from encoder
30. Test decoder with attention to encoder
31. Test decoder with cross-attention
32. Test decoder without BatchNorm
33. Test decoder with LayerNorm
34. Test decoder with GroupNorm
35. Test decoder with InstanceNorm
36. Test decoder with spectral norm
37. Test decoder with weight norm
38. Test deeper decoder than encoder
39. Test shallower decoder than encoder
40. Test decoder with residual blocks
41. Test decoder with deconvolutions
42. Test decoder with upsampling + conv
43. Test decoder with pixel shuffle
44. Test probabilistic decoder (Gaussian)
45. Test Bernoulli decoder
46. Test Categorical decoder
47. Test mixture density decoder
48. Test autoregressive decoder
49. Test decoder with memory
50. Test conditional decoder

### Latent Space (51-75)
51. Test latent_dim = 4
52. Test latent_dim = 8
53. Test latent_dim = 16 (current)
54. Test latent_dim = 32
55. Test latent_dim = 64
56. Test latent_dim = 128
57. Test latent_dim = 256
58. Test hierarchical latent (2 levels)
59. Test hierarchical latent (3 levels)
60. Test discrete latent (VQ-VAE)
61. Test categorical latent
62. Test mixture of Gaussians prior
63. Test von Mises-Fisher prior (spherical)
64. Test Wrapped Cauchy prior (hyperbolic)
65. Test Laplace prior
66. Test Student-t prior
67. Test flow-based prior (normalizing flows)
68. Test IAF posterior
69. Test MAF posterior
70. Test real-NVP posterior
71. Test Glow posterior
72. Test neural spline flows
73. Test continuous normalizing flows
74. Test FFJORD
75. Test latent ODE

### Attention Mechanisms (76-100)
76. Test self-attention over positions
77. Test multi-head attention (4 heads)
78. Test multi-head attention (8 heads)
79. Test multi-head attention (16 heads)
80. Test linear attention
81. Test sparse attention
82. Test local attention (window)
83. Test global + local attention
84. Test axial attention
85. Test cross-attention between drugs
86. Test graph attention
87. Test slot attention
88. Test perceiver-style attention
89. Test attention with position bias
90. Test relative position attention
91. Test rotary position embedding
92. Test ALiBi position encoding
93. Test flash attention
94. Test memory-efficient attention
95. Test attention pooling
96. Test set transformer
97. Test attention over mutations only
98. Test attention with learned queries
99. Test cross-modal attention
100. Test temporal attention (for sequences)

---

## Category 2: Loss Functions (101-200)

### Reconstruction Losses (101-125)
101. MSE loss (current)
102. MAE loss (L1)
103. Smooth L1 loss (Huber)
104. Cross-entropy for one-hot
105. Focal loss for imbalanced positions
106. Weighted MSE by position
107. Weighted MSE by mutation frequency
108. Weighted MSE by resistance importance
109. Per-position adaptive weights
110. Learned position weights
111. Cosine similarity loss
112. Contrastive reconstruction loss
113. Perceptual loss (learned features)
114. SSIM-style structured loss
115. Wasserstein distance
116. MMD (Maximum Mean Discrepancy)
117. Sinkhorn divergence
118. Energy-based reconstruction
119. Score matching
120. Denoising score matching
121. Noise contrastive estimation
122. InfoNCE reconstruction
123. Barlow Twins loss
124. VICReg loss
125. Mutual information maximization

### KL Divergence Variants (126-150)
126. Standard KL (current)
127. Reverse KL
128. Jensen-Shannon divergence
129. Alpha-divergence (alpha=0.5)
130. Alpha-divergence (alpha=2.0)
131. Renyi divergence
132. f-divergence
133. Free-bits KL (minimum per dimension)
134. Beta-VAE (beta=2)
135. Beta-VAE (beta=4)
136. Beta-VAE (beta=10)
137. Annealed KL (linear warmup)
138. Cyclical KL annealing
139. KL thresholding
140. Capacity-based KL
141. Delta-VAE
142. InfoVAE
143. Factor-VAE
144. Beta-TC-VAE
145. DIP-VAE-I
146. DIP-VAE-II
147. Wasserstein VAE
148. Stein VAE
149. Adversarial VAE
150. Two-stage VAE

### Ranking/Correlation Losses (151-175)
151. Pearson correlation loss (current)
152. Spearman correlation loss (differentiable)
153. Kendall tau loss
154. Margin ranking loss
155. Triplet ranking loss
156. Contrastive ranking loss
157. ListNet loss
158. ListMLE loss
159. ApproxNDCG loss
160. LambdaRank loss
161. RankNet loss
162. Soft ranking loss
163. Earth Mover's Distance for ranking
164. Rank correlation with temperature
165. Multi-scale ranking
166. Hierarchical ranking
167. Pairwise hinge loss
168. Ordinal regression loss
169. CORAL loss (ordinal)
170. Consistent rank logits
171. Soft labels for ranking
172. Expected ranking loss
173. Bayesian ranking
174. Rank-aware contrastive loss
175. Cross-entropy ranking

### Auxiliary Losses (176-200)
176. Drug classification loss
177. Mutation detection loss
178. Resistance level classification
179. Cross-resistance prediction
180. TAM pathway classification
181. Subtype classification
182. Gene region classification
183. Temporal prediction loss
184. Confidence calibration loss
185. Uncertainty estimation loss
186. Diversity regularization
187. Sparsity regularization
188. Orthogonality constraint
189. Lipschitz constraint
190. Gradient penalty
191. Spectral regularization
192. Information bottleneck
193. Disentanglement loss
194. Total correlation loss
195. Mutual information gap
196. Consistency regularization
197. Mixup loss
198. CutMix loss
199. Manifold mixup
200. Virtual adversarial training

---

## Category 3: Feature Engineering (201-300)

### Amino Acid Encoding (201-225)
201. One-hot encoding (current)
202. BLOSUM62 embedding
203. BLOSUM80 embedding
204. PAM250 embedding
205. Learned AA embedding (8-dim)
206. Learned AA embedding (16-dim)
207. Learned AA embedding (32-dim)
208. ESM-2 embedding (frozen)
209. ESM-2 embedding (fine-tuned)
210. ProtTrans embedding
211. UniRep embedding
212. SeqVec embedding
213. Evolutionary scale embedding
214. Physicochemical properties (7-dim)
215. AAindex properties (500+ indices)
216. Hydrophobicity scale
217. Charge + polarity
218. Size + volume
219. Secondary structure propensity
220. Solvent accessibility
221. Disorder propensity
222. Conservation score
223. Co-evolution features
224. Contact map embedding
225. 3D structure embedding

### Position Features (226-250)
226. Position index (normalized)
227. Sinusoidal position encoding
228. Learned position embedding
229. Relative position encoding
230. Distance to active site
231. Distance to drug binding site
232. Secondary structure type
233. Solvent accessibility
234. Conservation score per position
235. Mutation frequency per position
236. Entropy per position
237. Jensen-Shannon divergence per position
238. Co-evolution strength
239. Contact density
240. B-factor (flexibility)
241. pLDDT (AlphaFold confidence)
242. Functional domain annotation
243. Known resistance position flag
244. TAM position flag
245. Key mutation position flag
246. Synonymous mutation rate
247. Selection pressure (dN/dS)
248. Epistasis potential
249. Structural constraint
250. Evolutionary rate

### Mutation Features (251-275)
251. Mutation presence (binary)
252. Mutation type (conservative/radical)
253. BLOSUM score change
254. Physicochemical change magnitude
255. Charge change
256. Size change
257. Hydrophobicity change
258. Predicted stability change (ddG)
259. Predicted binding change
260. Known resistance mutation flag
261. Stanford penalty score
262. HIVdb mutation weight
263. Mutation frequency in dataset
264. Mutation co-occurrence frequency
265. Mutation exclusivity
266. Accessory vs primary mutation
267. Compensatory mutation flag
268. Reversion mutation flag
269. Polymorphism flag
270. Treatment-selected flag
271. Subtype-specific flag
272. Novel mutation flag
273. Insertion/deletion flag
274. Frameshift potential
275. Stop codon potential

### Sequence Context (276-300)
276. Local sequence window (±3 AA)
277. Local sequence window (±5 AA)
278. Local sequence window (±10 AA)
279. N-gram features (2-gram)
280. N-gram features (3-gram)
281. N-gram features (4-gram)
282. Skip-gram features
283. Motif presence (known motifs)
284. Regex pattern matching
285. Hidden Markov model states
286. Profile HMM log-odds
287. PSSM features
288. Sequence logo entropy
289. Information content
290. Relative entropy vs reference
291. Codon usage bias
292. GC content (local)
293. Nucleotide diversity
294. Recombination breakpoints
295. Hypermutation signatures
296. APOBEC signature
297. G-to-A hypermutation
298. Template switching evidence
299. Dual infection markers
300. Compartmentalization signal

---

## Category 4: Data Augmentation (301-350)

### Sequence Augmentation (301-325)
301. Random masking (5%)
302. Random masking (10%)
303. Random masking (20%)
304. Conservative AA substitution
305. Random AA substitution
306. BLOSUM-weighted substitution
307. Synonymous codon changes
308. Insertion augmentation
309. Deletion augmentation
310. Shuffling within regions
311. Reverse complement (if applicable)
312. Homolog substitution
313. Ancestral sequence reconstruction
314. Simulated evolution (short)
315. Simulated evolution (long)
316. Noise injection (Gaussian)
317. Noise injection (dropout)
318. Feature dropout
319. Cutout augmentation
320. Mixup augmentation
321. CutMix augmentation
322. Manifold mixup
323. AugMax (worst-case augmentation)
324. AutoAugment (learned)
325. RandAugment

### Resistance Augmentation (326-350)
326. Label smoothing (soft labels)
327. Resistance interpolation
328. Log-scale jittering
329. Rank-preserving noise
330. Confidence-weighted labels
331. Bootstrap resampling
332. SMOTE for rare classes
333. ADASYN
334. Borderline-SMOTE
335. Class-balanced sampling
336. Importance sampling
337. Hard example mining
338. Curriculum by resistance level
339. Anti-curriculum (hard first)
340. Self-paced learning
341. Co-training augmentation
342. Semi-supervised pseudo-labels
343. Noisy student training
344. Knowledge distillation labels
345. Ensemble soft labels
346. Cross-drug transfer labels
347. Stanford algorithm labels
348. Rule-based synthetic data
349. GAN-generated sequences
350. VAE-generated sequences

---

## Category 5: Training Strategies (351-450)

### Optimization (351-375)
351. SGD with momentum
352. Adam (current)
353. AdamW (weight decay)
354. RAdam
355. NAdam
356. Lamb
357. LARS
358. Adagrad
359. Adadelta
360. RMSprop
361. Adafactor
362. SM3
363. Shampoo
364. K-FAC
365. Natural gradient
366. Lookahead optimizer
367. SWA (Stochastic Weight Averaging)
368. EMA (Exponential Moving Average)
369. SAM (Sharpness-Aware Minimization)
370. ASAM
371. Gradient centralization
372. Gradient normalization
373. Gradient clipping (by norm)
374. Gradient clipping (by value)
375. PCGrad (conflicting gradients)

### Learning Rate Schedules (376-400)
376. Constant LR
377. Step decay
378. Multi-step decay
379. Exponential decay
380. Linear decay
381. Polynomial decay
382. Cosine annealing
383. Cosine annealing with restarts
384. Warm restarts
385. One-cycle policy
386. Triangular schedule
387. Cyclical LR
388. ReduceLROnPlateau
389. SGDR
390. Linear warmup + cosine
391. Linear warmup + linear decay
392. Exponential warmup
393. Gradual warmup
394. Layer-wise LR decay
395. Discriminative LR
396. Slanted triangular
397. Learning rate finder
398. Automatic LR range test
399. Hypergradient descent
400. Meta-learned schedule

### Regularization (401-425)
401. L1 regularization
402. L2 regularization (weight decay)
403. Elastic net
404. Dropout (0.1)
405. Dropout (0.2)
406. Dropout (0.3)
407. Dropout (0.5)
408. Spatial dropout
409. DropConnect
410. DropBlock
411. Stochastic depth
412. Shake-Shake
413. ShakeDrop
414. Cutout
415. Random erasing
416. Manifold regularization
417. Jacobian regularization
418. Spectral norm
419. Gradient penalty
420. Lipschitz constraint
421. Label smoothing
422. Confidence penalty
423. Entropy regularization
424. Mixup regularization
425. Knowledge distillation

### Batch Strategies (426-450)
426. Small batch (16)
427. Medium batch (32)
428. Large batch (64)
429. Large batch (128)
430. Very large batch (256)
431. Gradient accumulation
432. Micro-batching
433. Layer-wise batch size
434. Class-balanced batching
435. Hard example batching
436. Curriculum batching
437. Online hard negative mining
438. Importance-weighted batching
439. Stratified batching
440. Drug-stratified batching
441. Resistance-stratified batching
442. Cluster-balanced batching
443. Region-balanced batching
444. Time-balanced batching
445. Subtype-balanced batching
446. Dynamic batch sizing
447. Batch size warmup
448. Batch size annealing
449. Distributed batching
450. Asynchronous batching

---

## Category 6: Validation & Evaluation (451-550)

### Cross-Validation (451-475)
451. 5-fold CV
452. 10-fold CV
453. Leave-one-out CV
454. Stratified k-fold
455. Group k-fold (by patient)
456. Time-series split
457. Temporal holdout
458. Geographic holdout
459. Subtype holdout
460. Leave-one-drug-out
461. Leave-one-drug-class-out
462. Nested CV
463. Repeated CV (3x5)
464. Monte Carlo CV
465. Bootstrap validation
466. Out-of-bag validation
467. Adversarial validation
468. Distribution shift detection
469. Covariate shift correction
470. Domain adaptation validation
471. Multi-task CV
472. Transfer learning CV
473. Few-shot validation
474. Zero-shot validation
475. Continual learning validation

### Metrics (476-500)
476. Spearman correlation (current)
477. Pearson correlation
478. Kendall tau
479. R-squared
480. MSE
481. RMSE
482. MAE
483. MAPE
484. Concordance index
485. AUC-ROC (binarized)
486. AUC-PR (binarized)
487. F1 score (binarized)
488. Precision@k
489. Recall@k
490. NDCG
491. MAP
492. MRR
493. Calibration error
494. Expected calibration error
495. Brier score
496. Log loss
497. Explained variance
498. Coefficient of determination
499. Median absolute error
500. Max error

### External Validation (501-525)
501. Stanford HIVdb comparison
502. HIVdb algorithm correlation
503. Clinical outcome correlation
504. Treatment response prediction
505. Time to failure prediction
506. Viral load correlation
507. CD4 count correlation
508. Cross-cohort validation (US)
509. Cross-cohort validation (Europe)
510. Cross-cohort validation (Africa)
511. Cross-cohort validation (Asia)
512. Subtype B validation
513. Subtype C validation
514. Subtype A validation
515. CRF validation
516. LANL database validation
517. UK Drug Resistance Database
518. EuResist validation
519. Swiss HIV Cohort
520. SHCS validation
521. IeDEA validation
522. CASCADE validation
523. ACTG trials validation
524. Prospective validation
525. Clinical trial prediction

### Interpretability Validation (526-550)
526. Known mutation recovery
527. Stanford penalty alignment
528. Key mutation attention
529. Mechanism explanation match
530. Expert review
531. Literature validation
532. Crystal structure alignment
533. Binding site proximity
534. Epistasis recovery
535. Cross-resistance explanation
536. TAM pathway detection
537. Q151M complex detection
538. K65R pathway detection
539. M184V effect validation
540. Novel mutation prediction
541. Compensatory mutation detection
542. Fitness cost prediction
543. Reversion prediction
544. Treatment history alignment
545. Resistance mechanism match
546. Structural rationale
547. Evolutionary rationale
548. Biochemical validation
549. In vitro correlation
550. Animal model correlation

---

## Category 7: Drug-Specific Experiments (551-650)

### PI Drugs (551-575)
551. LPV-specific model
552. DRV-specific model
553. ATV-specific model
554. Cross-resistance PI model
555. Boosted PI model
556. PI major mutation focus
557. PI minor mutation focus
558. PI fitness landscape
559. PI binding site features
560. PI flap dynamics features
561. PI active site features
562. PI resistance pathway model
563. PI accumulation model
564. PI sequential mutation model
565. PI genetic barrier model
566. PI fold change prediction
567. PI IC50 prediction
568. PI clinical cutoff prediction
569. PI-NNRTI cross-prediction
570. PI drug interaction model
571. PI pharmacokinetic adjustment
572. PI adherence impact model
573. PI subtype-specific model
574. PI treatment history model
575. PI salvage therapy model

### NRTI Drugs (576-600)
576. 3TC/FTC-specific model
577. TDF-specific model
578. AZT-specific model
579. ABC-specific model
580. TAM-focused model
581. TAM1 pathway model
582. TAM2 pathway model
583. K65R pathway model
584. M184V escape model
585. Q151M complex model
586. T69 insertion model
587. NRTI cross-resistance matrix
588. Thymidine analog model
589. Cytidine analog model
590. Adenosine analog model
591. NRTI fitness cost model
592. NRTI replication capacity
593. NRTI incorporation model
594. NRTI excision model
595. NRTI binding affinity
596. NRTI chain termination
597. NRTI phosphorylation
598. NRTI intracellular levels
599. NRTI drug-drug interaction
600. NRTI backbone selection

### NNRTI Drugs (601-625)
601. EFV-specific model
602. NVP-specific model
603. RPV-specific model
604. ETR-specific model
605. DOR-specific model
606. First-gen NNRTI model
607. Second-gen NNRTI model
608. NNRTI binding pocket model
609. NNRTI allosteric model
610. NNRTI E138 pathway
611. NNRTI K103N pathway
612. NNRTI Y181C pathway
613. NNRTI Y188 pathway
614. NNRTI cross-resistance model
615. NNRTI accumulation model
616. NNRTI genetic barrier model
617. NNRTI single mutation model
618. NNRTI multi-mutation model
619. NNRTI IC50 prediction
620. NNRTI clinical cutoff
621. NNRTI subtype effect
622. NNRTI baseline polymorphism
623. NNRTI transmitted resistance
624. NNRTI acquired resistance
625. NNRTI weight-based scoring

### INI Drugs (626-650)
626. RAL-specific model
627. EVG-specific model
628. DTG-specific model
629. BIC-specific model
630. CAB-specific model
631. First-gen INI model
632. Second-gen INI model
633. INI binding site model
634. INI strand transfer model
635. INI 3' processing model
636. INI Q148 pathway
637. INI N155 pathway
638. INI Y143 pathway
639. INI G118R pathway
640. INI cross-resistance model
641. INI genetic barrier model
642. INI fitness cost model
643. INI R263K model
644. INI S153 pathway
645. INI IC50 prediction
646. INI fold change model
647. INI clinical cutoff
648. INI transmitted resistance
649. INI long-acting formulation
650. INI combination prediction

---

## Category 8: Advanced Methods (651-750)

### Meta-Learning (651-675)
651. MAML
652. Reptile
653. FOMAML
654. ANIL
655. ProtoNet
656. Matching Networks
657. Relation Networks
658. TADAM
659. MetaOptNet
660. LEO
661. Meta-SGD
662. CAVIA
663. CNP (Conditional Neural Processes)
664. ANP (Attentive Neural Processes)
665. Meta-transfer learning
666. Cross-task meta-learning
667. Continual meta-learning
668. Online meta-learning
669. Multi-domain meta-learning
670. Hierarchical meta-learning
671. Task-agnostic meta-learning
672. Few-shot drug adaptation
673. Zero-shot drug prediction
674. Meta-learned initialization
675. Meta-learned optimizer

### Transfer Learning (676-700)
676. Pretrain on PI, transfer to INI
677. Pretrain on all, fine-tune each
678. Layer freezing transfer
679. Gradual unfreezing
680. Discriminative fine-tuning
681. ULMFiT-style transfer
682. Domain adaptation
683. Domain adversarial training
684. MMD domain adaptation
685. CORAL domain adaptation
686. Optimal transport adaptation
687. Multi-source transfer
688. Negative transfer detection
689. Selective transfer
690. Knowledge distillation transfer
691. Feature-based transfer
692. Instance-based transfer
693. Parameter-based transfer
694. Relational transfer
695. Cross-gene transfer
696. Cross-pathogen transfer
697. Cross-species transfer
698. Pre-training on UniProt
699. Pre-training on PDB
700. Pre-training on clinical data

### Uncertainty Quantification (701-725)
701. MC Dropout
702. Deep Ensembles
703. Bayesian Neural Networks
704. Variational inference
705. Laplace approximation
706. SWAG
707. SNGP
708. DUE (Deterministic UE)
709. Evidential deep learning
710. Dirichlet networks
711. Gaussian processes
712. Neural processes
713. Conformal prediction
714. Calibration training
715. Temperature scaling
716. Platt scaling
717. Isotonic regression
718. Beta calibration
719. Focal calibration
720. Uncertainty decomposition
721. Aleatoric uncertainty
722. Epistemic uncertainty
723. Out-of-distribution detection
724. Selective prediction
725. Active learning with uncertainty

### Graph Neural Networks (726-750)
726. GCN for mutation graph
727. GAT for mutation attention
728. GraphSAGE
729. GIN (Graph Isomorphism)
730. MPNN
731. SchNet
732. DimeNet
733. PaiNN
734. EGNN
735. SE(3)-Transformer
736. Residue contact graph
737. Mutation co-occurrence graph
738. Resistance pathway graph
739. Drug similarity graph
740. Patient-mutation graph
741. Temporal mutation graph
742. Phylogenetic graph
743. Protein structure graph
744. Binding site graph
745. Interaction network
746. Hierarchical graph
747. Heterogeneous graph
748. Dynamic graph
749. Graph contrastive learning
750. Graph generation

---

## Category 9: Multi-Task & Multi-Modal (751-850)

### Multi-Task Learning (751-775)
751. All drugs jointly
752. Within-class joint training
753. Cross-class training
754. Hard parameter sharing
755. Soft parameter sharing
756. Cross-stitch networks
757. NDDR-CNN
758. Sluice networks
759. Task routing
760. Task attention
761. Progressive training
762. Curriculum multi-task
763. GradNorm
764. Uncertainty weighting
765. DWA (Dynamic Weight Average)
766. MGDA
767. CAGrad
768. PCGrad
769. Gradient vaccine
770. Nash-MTL
771. Auto-Lambda
772. Meta-weight-net
773. Auxiliary task learning
774. Task grouping
775. Negative transfer avoidance

### Multi-Modal Fusion (776-800)
776. Sequence + structure
777. Sequence + phylogeny
778. Sequence + clinical
779. Sequence + drug properties
780. Early fusion (concatenation)
781. Late fusion (ensemble)
782. Middle fusion
783. Attention fusion
784. Gated fusion
785. Tensor fusion
786. Bilinear fusion
787. Low-rank fusion
788. FiLM conditioning
789. Cross-modal attention
790. Multi-modal transformer
791. Perceiver-style fusion
792. CLIP-style alignment
793. Contrastive fusion
794. Canonical correlation
795. Partial modal learning
796. Missing modality handling
797. Modal dropout
798. Modal-specific encoders
799. Shared + private decomposition
800. Disentangled multi-modal

### Ensemble Methods (801-825)
801. Simple averaging
802. Weighted averaging
803. Stacking
804. Blending
805. Bagging
806. Boosting
807. AdaBoost
808. Gradient boosting
809. XGBoost
810. LightGBM
811. CatBoost
812. Random subspace
813. Feature bagging
814. Snapshot ensembles
815. Cyclic ensembles
816. FGE (Fast Geometric Ensembles)
817. Hyperparameter ensembles
818. Architecture ensembles
819. Loss function ensembles
820. Data augmentation ensembles
821. Dropout ensembles
822. Multi-seed ensembles
823. Cross-validation ensembles
824. Diverse ensemble selection
825. Ensemble distillation

### Semi-Supervised Learning (826-850)
826. Pseudo-labeling
827. Self-training
828. Co-training
829. Tri-training
830. Mean teacher
831. Temporal ensembling
832. Virtual adversarial training
833. MixMatch
834. FixMatch
835. UDA (Unsupervised Data Aug)
836. ReMixMatch
837. FlexMatch
838. Contrastive learning (SimCLR)
839. BYOL
840. MoCo
841. SwAV
842. DINO
843. Barlow Twins
844. VICReg
845. SimSiam
846. Label propagation
847. Graph-based semi-supervised
848. Transductive learning
849. Active semi-supervised
850. Open-set semi-supervised

---

## Category 10: Biological Insights (851-950)

### Resistance Mechanisms (851-875)
851. Model drug binding affinity
852. Model enzyme activity
853. Model viral fitness
854. Model replication capacity
855. Model processivity
856. Model fidelity
857. Model incorporation efficiency
858. Model excision rate
859. Model chain termination
860. Model RT/RNase H coupling
861. Model polymerase vs RNase
862. Model primer unblocking
863. Model NRTI discrimination
864. Model NNRTI allosteric effect
865. Model INI strand transfer
866. Model INI 3' processing
867. Model protease cleavage
868. Model substrate recognition
869. Model Gag-Pol processing
870. Model drug efflux
871. Model drug metabolism
872. Model drug penetration
873. Model intracellular activation
874. Model protein stability
875. Model protein folding

### Evolutionary Dynamics (876-900)
876. Model mutation rate
877. Model selection pressure
878. Model genetic drift
879. Model population size
880. Model bottleneck effects
881. Model founder effects
882. Model recombination
883. Model template switching
884. Model compartmentalization
885. Model sanctuary sites
886. Model tissue reservoirs
887. Model latent reservoir
888. Model rebound dynamics
889. Model resistance emergence
890. Model resistance reversion
891. Model fitness landscape
892. Model epistasis
893. Model compensatory evolution
894. Model convergent evolution
895. Model parallel evolution
896. Model within-host evolution
897. Model between-host transmission
898. Model treatment selection
899. Model immune selection
900. Model CTL escape

### Cross-Resistance Patterns (901-925)
901. Model within-class cross-resistance
902. Model between-class cross-resistance
903. Model NRTI-NNRTI interactions
904. Model PI cross-resistance matrix
905. Model INI cross-resistance
906. Model TAM spectrum
907. Model K65R spectrum
908. Model M184V effects
909. Model E138K spectrum
910. Model Q148 effects
911. Model hypersusceptibility
912. Model antagonistic mutations
913. Model synergistic mutations
914. Model incompatible mutations
915. Model resistance trade-offs
916. Model drug sequencing
917. Model treatment cycling
918. Model treatment switching
919. Model salvage therapy selection
920. Model resistance testing timing
921. Model predicted trajectory
922. Model treatment optimization
923. Model regimen selection
924. Model adherence impact
925. Model drug level impact

### Clinical Translation (926-950)
926. Map to clinical categories
927. Map to Stanford levels
928. Map to ANRS algorithms
929. Map to Rega algorithms
930. Predict treatment outcome
931. Predict viral suppression
932. Predict treatment failure
933. Predict time to failure
934. Predict CD4 response
935. Predict immune reconstitution
936. Predict toxicity risk
937. Predict drug interactions
938. Predict adherence requirements
939. Predict resistance emergence
940. Predict transmitted resistance
941. Predict minority variants
942. Risk stratification
943. Treatment prioritization
944. Resource-limited settings
945. Point-of-care testing
946. Real-time decision support
947. Electronic health record integration
948. Treatment guideline alignment
949. Regulatory compliance
950. Quality assurance

---

## Category 11: Infrastructure & Scalability (951-1000)

### Efficiency Optimizations (951-975)
951. Mixed precision training (FP16)
952. Gradient checkpointing
953. Memory-efficient attention
954. Flash attention
955. Activation recomputation
956. Micro-batching
957. Pipeline parallelism
958. Data parallelism
959. Model parallelism
960. Tensor parallelism
961. ZeRO optimization
962. Offloading to CPU
963. Sparse training
964. Pruning
965. Quantization (INT8)
966. Quantization-aware training
967. Knowledge distillation
968. Neural architecture search
969. AutoML
970. Hyperparameter optimization (Optuna)
971. Bayesian optimization
972. Population-based training
973. Efficient data loading
974. Caching strategies
975. Distributed training

### Deployment & Monitoring (976-1000)
976. Model serialization
977. ONNX export
978. TorchScript
979. TensorRT optimization
980. REST API endpoint
981. Batch inference
982. Real-time inference
983. Edge deployment
984. Mobile deployment
985. Browser deployment (WASM)
986. Model versioning
987. A/B testing
988. Canary deployment
989. Model monitoring
990. Drift detection
991. Performance monitoring
992. Error tracking
993. Logging infrastructure
994. Alerting system
995. Automated retraining
996. Continuous integration
997. Continuous deployment
998. Documentation
999. User interface
1000. Clinical workflow integration

---

## Prioritization Matrix

### High Impact, Low Effort (Do First)
- #151-175: Ranking loss variants
- #201-225: Better AA encodings
- #251-275: Mutation features
- #476-500: Additional metrics
- #501-525: External validation

### High Impact, High Effort (Plan Carefully)
- #651-675: Meta-learning
- #701-725: Uncertainty quantification
- #751-775: Multi-task learning
- #926-950: Clinical translation

### Low Impact, Low Effort (Quick Wins)
- #351-375: Optimizer experiments
- #376-400: LR schedules
- #401-425: Regularization

### Low Impact, High Effort (Deprioritize)
- #726-750: Graph neural networks
- #776-800: Multi-modal fusion
- #951-975: Efficiency optimizations

---

## Execution Strategy

### Phase 1: Quick Experiments (Week 1-2)
- Items 1-50: Architecture variants
- Items 101-150: Loss function variants
- Items 351-400: Training strategies

### Phase 2: Feature Engineering (Week 3-4)
- Items 201-300: Feature engineering
- Items 301-350: Data augmentation

### Phase 3: Drug-Specific (Week 5-6)
- Items 551-650: Drug-specific models
- Items 901-925: Cross-resistance patterns

### Phase 4: Advanced Methods (Week 7-8)
- Items 651-750: Meta-learning, transfer, uncertainty
- Items 751-850: Multi-task, multi-modal

### Phase 5: Validation & Deployment (Week 9-10)
- Items 451-550: Validation & evaluation
- Items 926-1000: Clinical translation, deployment

---

## Tracking Template

For each experiment:
```
ID: [1-1000]
Name: [Description]
Hypothesis: [What we expect]
Baseline: [Current performance]
Result: [Observed performance]
Delta: [Improvement/regression]
Notes: [Observations]
Status: [Pending/Running/Complete/Failed]
Priority: [High/Medium/Low]
Effort: [Hours]
```

---

**Total Experiments: 1000**
**Estimated Duration: 10-12 weeks (focused effort)**
**Expected Outcome: Identify top 20-30 improvements to implement**
